A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive patients.
Objective: to explain anti-HBc is a new predictor of peginterferon treatment response.
Type of research: clinical trial.
Method of data collection: Serum samples were collected every 12 weeks, and were tested.
Type of data: clinical data.
- 2021-05-26 first online, published, posted